Drug intelligence / Profile preview

telaglenastat

Development stage: Phase 2
Lead developer: Synhale Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Telaglenastat is an orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. It selectively and irreversibly inhibits glutaminase, an enzyme involved in the metabolism of glutamine, which is crucial for the growth and survival of cancer cells. Telaglenastat is being developed by Cornerstone Pharmaceuticals and has been investigated in various clinical trials for solid and hematologic cancers.

Other names: CB-839CB839CB 839

Targets

GLS1 (Glutaminase 1)

Beyond the preview

Go deeper on telaglenastat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on telaglenastat.

Explore the full profile